Mar 27 |
Earnings Scheduled For March 27, 2024
|
Mar 20 |
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
|
Mar 13 |
BioCardia and StemCardia partners for heart failure treatment candidate
|
Mar 13 |
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
|
Mar 12 |
BioCardia spikes after Medicare coverage for cell therapy trial
|
Mar 12 |
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
|
Mar 4 |
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
|
Feb 14 |
BioCardia to sell 3.02M shares for holders
|
Feb 8 |
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA
|
Jan 31 |
BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference
|